These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32903474)

  • 1. Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional Study.
    von Bernuth K; Seidel P; Krebs J; Lehmann M; Neumann B; Konrad N; Opitz-Welke A
    Front Psychiatry; 2020; 11():794. PubMed ID: 32903474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accessing opioid agonist treatment in prison in England and Scotland remains problematic - the views of people with lived experience.
    Webster R; Fearns C; Harriott P; Millar L; Simpson J; Wallace J; Wheatley M
    Int J Prison Health (2024); 2024 May; 20(2):143-155. PubMed ID: 38984599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability of opioid agonist treatment and critical incidents in Forensic Clinics for Dependency Diseases in Germany.
    Reiners S; Opitz-Welke A; Konrad N; Voulgaris A
    Front Psychiatry; 2022; 13():961549. PubMed ID: 36159944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
    Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L
    PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in prisons.
    Komalasari R; Wilson S; Haw S
    Int J Drug Policy; 2021 Jan; 87():102978. PubMed ID: 33129135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
    Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
    Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons-Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids.
    Buadze A; Baggio S; Schleifer R; Aeberhard E; Wolff H; Schneeberger A; Liebrenz M
    Front Psychiatry; 2020; 11():395. PubMed ID: 32477183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
    Oliva EM; Harris AH; Trafton JA; Gordon AJ
    Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia.
    Larney S; Cama E; Nelson E; Larance B; Degenhardt L
    Drug Alcohol Rev; 2016 Nov; 35(6):686-692. PubMed ID: 26711174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
    Favrod-Coune T; Baroudi M; Casillas A; Rieder JP; Gétaz L; Barro J; Gaspoz JM; Broers B; Wolff H
    Swiss Med Wkly; 2013; 143():w13898. PubMed ID: 24186493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy.
    Kutsa O; Marcus R; Bojko MJ; Zelenev A; Mazhnaya A; Dvoriak S; Filippovych S; Altice FL
    J Int AIDS Soc; 2016; 19(4 Suppl 3):20897. PubMed ID: 27435717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
    Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine.
    Mazhnaya A; Marcus R; Bojko MJ; Zelenev A; Makarenko I; Pykalo I; Filippovych S; Dvoriak S; Altice FL
    J Acquir Immune Defic Syndr; 2018 Nov; 79(3):288-295. PubMed ID: 30312275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid users with comorbid hepatitis C spent more time in agonist therapy: A 6-year observational study in Taiwan.
    Chen HM; Lu TH; Chang KC; Lee KY; Cheng CM
    Addict Behav; 2017 Sep; 72():133-137. PubMed ID: 28395249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.
    Bodkin C; Bondy S; Regenstreif L; Kiefer L; Kouyoumdjian F
    BMJ Open; 2021 Nov; 11(11):e048944. PubMed ID: 34794988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting.
    Hariri S; Sharafkhah M; Alavi M; Roshandel G; Fazel A; Amiriani T; Motamed-Gorji N; Bazazan A; Merat S; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Aug; 17(1):56. PubMed ID: 32795371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project.
    Rojas Rojas T; Di Beo V; Delorme J; Barre T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B; Marcellin F
    Int J Drug Policy; 2019 Oct; 72():61-68. PubMed ID: 31129024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.